scholarly journals Effect of Delayed Clozapine Initiation on Acute Treatment Response in Treatment-Resistant Schizophrenia

2021 ◽  
Vol 24 (2) ◽  
pp. 52-59
Author(s):  
So Yung Yang ◽  
Jung-Kyu Choi ◽  
Sunyoung Park ◽  
Jaesub Park
Keyword(s):  
Treatment Response ◽  
Acute Treatment ◽  
Treatment Resistant

Baseline Working Memory Predicted Response to Low-Dose Ketamine Infusion in Patients with Treatment-Resistant Depression

2021 ◽  
Author(s):  
Mu-Hong Chen ◽  
Wei-Chen Lin ◽  
Cheng-Ta Li ◽  
Shih-Jen Tsai ◽  
Hui-Ju Wu ◽  
...  
Keyword(s):  
Working Memory ◽  
Depressive Symptoms ◽  
Treatment Response ◽  
Low Dose ◽  
Memory Function ◽  
Treatment Resistant Depression ◽  
Treatment Resistant ◽  
Ketamine Infusion ◽  
Treatment Groups ◽  
Resistant Depression

Abstract Introduction Pretreatment neurocognitive function may predict the treatment response to low-dose ketamine infusion in patients with treatment-resistant depression (TRD). However, the association between working memory function at baseline and the antidepressant efficacy of ketamine infusion remains unclear. Methods A total of 71 patients with TRD were randomized to one of three treatment groups: 0.5 mg/kg ketamine, 0.2 mg/kg ketamine, or normal saline. Depressive symptoms were measured using the 17-item Hamilton Depression Rating Scale (HDRS) at baseline and after treatment. Cognitive function was evaluated using working memory and go-no-go tasks at baseline. Results A generalized linear model with adjustments for demographic characteristics, treatment groups, and total HDRS scores at baseline revealed only a significant effect of working memory function (correct responses and omissions) on the changes in depressive symptoms measured by HDRS at baseline (F=12.862, p<0.05). Correlation analysis further showed a negative relationship (r=0.519, p=0.027) between pretreatment working memory function and changes in HDRS scores in the 0.5 mg/kg ketamine group. Discussion An inverse relationship between pretreatment working memory function and treatment response to ketamine infusion may confirm that low-dose ketamine infusion is beneficial and should be reserved for patients with TRD.

scholarly journals Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology

2017 ◽  
Vol 174 (3) ◽  
pp. 216-229 ◽  
Author(s):  
Oliver D. Howes ◽  
Rob McCutcheon ◽  
Ofer Agid ◽  
Andrea de Bartolomeis ◽  
Nico J.M. van Beveren ◽  
...  
Keyword(s):  
Treatment Response ◽  
Working Group ◽  
Group Consensus ◽  
Consensus Guidelines ◽  
Treatment Resistant

scholarly journals Migraine polygenic risk score associates with efficacy of migraine-specific drugs

2019 ◽  
Vol 5 (6) ◽  
pp. e364 ◽  
Author(s):  
Lisette J.A. Kogelman ◽  
Ann-Louise Esserlind ◽  
Anne Francke Christensen ◽  
Swapnil Awasthi ◽  
Stephan Ripke ◽  
...  
Keyword(s):  
Treatment Response ◽  
Risk Score ◽  
Acute Treatment ◽  
Genome Wide Association Study ◽  
Positive Response ◽  
Migraine Treatment ◽  
Polygenic Risk Score ◽  
Semistructured Interview ◽  
Polygenic Risk ◽  
Twofold Increase

ObjectiveTo assess whether the polygenic risk score (PRS) for migraine is associated with acute and/or prophylactic migraine treatment response.MethodsWe interviewed 2,219 unrelated patients at the Danish Headache Center using a semistructured interview to diagnose migraine and assess acute and prophylactic drug response. All patients were genotyped. A PRS was calculated with the linkage disequilibrium pred algorithm using summary statistics from the most recent migraine genome-wide association study comprising ∼375,000 cases and controls. The PRS was scaled to a unit corresponding to a twofold increase in migraine risk, using 929 unrelated Danish controls as reference. The association of the PRS with treatment response was assessed by logistic regression, and the predictive power of the model by area under the curve using a case-control design with treatment response as outcome.ResultsA twofold increase in migraine risk associates with positive response to migraine-specific acute treatment (odds ratio [OR] = 1.25 [95% confidence interval (CI) = 1.05–1.49]). The association between migraine risk and migraine-specific acute treatment was replicated in an independent cohort consisting of 5,616 triptan users with prescription history (OR = 3.20 [95% CI = 1.26–8.14]). No association was found for acute treatment with non–migraine-specific weak analgesics and prophylactic treatment response.ConclusionsThe migraine PRS can significantly identify subgroups of patients with a higher-than-average likelihood of a positive response to triptans, which provides a first step toward genetics-based precision medicine in migraine.

Acute treatment-resistant post-partum necrotising myopathy with anti-Ro52/TRIM21 antibodies treated with rituximab

2015 ◽  
Vol 35 (9) ◽  
pp. 1603-1605 ◽  
Author(s):  
Savvas Psarelis ◽  
Doros Polydorou ◽  
Sophia Corsava ◽  
Constantinos Aristotelous
Keyword(s):  
Acute Treatment ◽  
Post Partum ◽  
Treatment Resistant

Duration of untreated psychosis may predict acute treatment response in first-episode schizophrenia

2004 ◽  
Vol 38 (2) ◽  
pp. 163-168 ◽  
Author(s):  
Alp Üçok ◽  
Aslιhan Polat ◽  
Aysun Genç ◽  
Sibel Çakιr ◽  
Nurten Turan
Keyword(s):  
Treatment Response ◽  
Acute Treatment ◽  
First Episode ◽  
Duration Of Untreated Psychosis ◽  
First Episode Schizophrenia

P.3.c.009 Predominant clinical dimension and acute treatment response in schizophrenic inpatients

2011 ◽  
Vol 21 ◽  
pp. S472-S473
Author(s):  
M. Buoli ◽  
M. Serati ◽  
A. Caldiroli ◽  
A.C. Altamura
Keyword(s):  
Treatment Response ◽  
Acute Treatment
Sign in / Sign up

Export Citation Format

Share Document